

# Alexander Knuth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6854149/publications.pdf>

Version: 2024-02-01

167  
papers

11,123  
citations

43973

48  
h-index

38300

95  
g-index

170  
all docs

170  
docs citations

170  
times ranked

12808  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. <i>Journal of Clinical Oncology</i> , 2008, 26, 1435-1442.	0.8	689
2	Simultaneous Humoral and Cellular Immune Response against Cancer-Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2-binding Peptide Epitopes. <i>Journal of Experimental Medicine</i> , 1998, 187, 265-270.	4.2	668
3	A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens. <i>Journal of Experimental Medicine</i> , 1998, 187, 1349-1354.	4.2	642
4	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
5	Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation. <i>Journal of Immunology</i> , 2012, 189, 558-566.	0.4	363
6	NY-ESO-1: Review of an Immunogenic Tumor Antigen. <i>Advances in Cancer Research</i> , 2006, 95, 1-30.	1.9	311
7	Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin. <i>Journal of Immunology</i> , 2007, 178, 320-329.	0.4	309
8	Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. <i>International Journal of Cancer</i> , 1997, 71, 142-147.	2.3	287
9	Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. , 1996, 67, 54-62.		261
10	Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. , 1996, 66, 470-476.		243
11	Aldara activates TLR7-independent immune defence. <i>Nature Communications</i> , 2013, 4, 1560.	5.8	211
12	Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14453-14458.	3.3	202
13	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. , 1996, 66, 162-169.		200
14	Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1-Expressing Melanoma. <i>Journal of Experimental Medicine</i> , 2000, 191, 625-630.	4.2	196
15	Humoral immune responses of cancer patients against Cancer-Testis-antigen NY-ESO-1: Correlation with clinical events. , 1999, 84, 506-510.		194
16	SSX: A multigene family with several members transcribed in normal testis and human cancer. , 1997, 72, 965-971.		190
17	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8862-8867.	3.3	179
18	Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 2526-2531.	0.8	174

#	ARTICLE	IF	CITATIONS
19	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. <i>Journal of Immunology</i> , 2000, 165, 948-955.	0.4	161
20	Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. <i>Cancer Research</i> , 2002, 62, 4041-7.	0.4	149
21	Antigens recognized by autologous antibody in patients with renal-cell carcinoma. , 1999, 83, 456-464.		146
22	Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. <i>OncImmunology</i> , 2013, 2, e23562.	2.1	138
23	Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response. <i>Immunity</i> , 2015, 42, 767-777.	6.6	135
24	Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. <i>Journal of Immunotherapy</i> , 2010, 33, 848-858.	1.2	131
25	$\hat{\text{I}}^3$ -Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo. <i>PLoS ONE</i> , 2011, 6, e28217.	1.1	127
26	Consensus nomenclature for CD8 <sup>+</sup> T cell phenotypes in cancer. <i>OncImmunology</i> , 2015, 4, e998538.	2.1	119
27	New Derivatives of Vitamin B12 Show Preferential Targeting of Tumors. <i>Cancer Research</i> , 2008, 68, 2904-2911.	0.4	117
28	Clinical cancer vaccine trials. <i>Current Opinion in Immunology</i> , 2002, 14, 178-182.	2.4	115
29	Identification of cancer/testis genes by database mining and mRNA expression analysis. <i>International Journal of Cancer</i> , 2002, 98, 485-492.	2.3	111
30	Rational development of high-affinity T-cell receptor-like antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5784-5788.	3.3	109
31	Clonal expansion of melan a-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. <i>International Journal of Cancer</i> , 2000, 86, 538-547.	2.3	105
32	Particle size and activation threshold: a new dimension of danger signaling. <i>Blood</i> , 2010, 115, 4533-4541.	0.6	103
33	Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. <i>Breast Cancer Research</i> , 2005, 7, R617-26.	2.2	84
34	Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 381-394.	2.0	84
35	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11813-11818.	3.3	83
36	Antigen-specific immunotherapy and cancer vaccines. <i>International Journal of Cancer</i> , 2003, 106, 817-820.	2.3	83

#	ARTICLE	IF	CITATIONS
37	Virus-like particles for vaccination against cancer. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1579.	3.3	74
38	Quantitative Computed Tomography Liver Perfusion Imaging Using Dynamic Spiral Scanning With Variable Pitch. <i>Investigative Radiology</i> , 2010, 45, 419-426.	3.5	71
39	Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. <i>International Journal of Cancer</i> , 2011, 129, 832-838.	2.3	69
40	Treatment of POEMS syndrome with bevacizumab. <i>Haematologica</i> , 2007, 92, 1438-1439.	1.7	67
41	Vaccination for Malignant Melanoma: Recent Developments. <i>Oncology</i> , 2001, 60, 1-7.	0.9	65
42	NY-ESO-1 protein expression in primary breast carcinoma and metastases" correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. <i>International Journal of Cancer</i> , 2007, 120, 2411-2417.	2.3	65
43	Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2010, 62, 1224-1235.	6.7	65
44	Frequent expression of the novel cancer testis antigen MAGE-C2/CT40 in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2009, 124, 352-357.	2.3	63
45	Efficient <i>in vivo</i> Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 861-870.	3.2	63
46	Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1005-1012.	1.1	61
47	Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature. <i>Clinical Cancer Research</i> , 2013, 19, 4843-4853.	3.2	60
48	Intratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma. <i>Cancer Research</i> , 2005, 65, 3937-3941.	0.4	56
49	Cellular immune response to human renal-cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-Lymphocyte (CTL) clones. <i>International Journal of Cancer</i> , 1994, 59, 837-842.	2.3	55
50	NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1723-1731.	2.0	55
51	CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. <i>Cancer and Metastasis Reviews</i> , 1999, 18, 143-150.	2.7	52
52	Quantitative Perfusion Analysis of Malignant Liver Tumors. <i>Investigative Radiology</i> , 2012, 47, 18-24.	3.5	52
53	Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m <sup>2</sup> Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer. <i>Oncology</i> , 2006, 70, 141-146.	0.9	51
54	Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2010, 16, 3562-3570.	3.2	51

#	ARTICLE	IF	CITATIONS
55	Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs. <i>Journal of Immunology</i> , 2003, 170, 1191-1196.	0.4	50
56	Automated tube potential selection for standard chest and abdominal CT in follow-up patients with testicular cancer: comparison with fixed tube potential. <i>European Radiology</i> , 2012, 22, 1937-1945.	2.3	49
57	Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 144-147.	2.0	48
58	MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer. <i>PLoS ONE</i> , 2011, 6, e21366.	1.1	47
59	Lysis of human pancreatic adenocarcinoma cells by autologous hla-class I-restricted cytolytic T-lymphocyte (CTL) clones. <i>International Journal of Cancer</i> , 1993, 54, 636-644.	2.3	46
60	Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. <i>Journal of Immunological Methods</i> , 2003, 278, 57-66.	0.6	46
61	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. <i>Cancer Research</i> , 2012, 72, 1672-1682.	0.4	46
62	Simultaneous cytoplasmic and nuclear protein expression of melanoma antigenâ€A family and NYâ€ESOâ€1 cancerâ€testis antigens represents an independent marker for poor survival in head and neck cancer. <i>International Journal of Cancer</i> , 2014, 135, 1142-1152.	2.3	46
63	Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 1994, 39, 93-99.	2.0	42
64	Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases. <i>Clinical Cancer Research</i> , 2006, 12, 2745-2751.	3.2	42
65	Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients. <i>PLoS ONE</i> , 2011, 6, e21418.	1.1	42
66	Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Radioembolization of Liver Metastases. <i>Investigative Radiology</i> , 2013, 48, 787-794.	3.5	42
67	$\beta_6$ -integrin serves as a novel serum tumor marker for colorectal carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 678-685.	2.3	42
68	Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial. <i>Oncology</i> , 2012, 83, 1-9.	0.9	41
69	Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. , 2019, 7, 114.		41
70	LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. <i>Cancer Immunity</i> , 2007, 7, 16.	3.2	41
71	MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. <i>Modern Pathology</i> , 2011, 24, 829-835.	2.9	39
72	Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial. <i>Journal of Cancer</i> , 2013, 4, 597-605.	1.2	39

#	ARTICLE	IF	CITATIONS
73	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 1015.	2.2	39
74	Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. <i>Cancer Immunity</i> , 2005, 5, 11.	3.2	39
75	A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. <i>Journal of Immunology</i> , 2007, 178, 2617-21.	0.4	38
76	Targeted therapy of renal cell carcinoma: Synergistic activity of cG250 $\alpha$ TNF and IFN $\gamma$ . <i>International Journal of Cancer</i> , 2009, 125, 115-123.	2.3	37
77	Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. <i>Cancer Genetics and Cytogenetics</i> , 1995, 80, 138-149.	1.0	35
78	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1079-1099.	0.6	34
79	NY-BR-1 is a Differentiation Antigen of the Mammary Gland. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 77-83.	0.6	33
80	Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer. , 1999, 81, 125-133.		32
81	Strong Immunogenic Potential of a B7 Retroviral Expression Vector: Generation of HLA-B7-Restricted CTL Response Against Selectable Marker Genes. <i>Human Gene Therapy</i> , 1998, 9, 53-62.	1.4	31
82	Structure-Activity Profiles of Ab-Derived TNF Fusion Proteins. <i>Journal of Immunology</i> , 2006, 177, 2423-2430.	0.4	31
83	The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 2635-2642.	2.3	31
84	Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. <i>Cancer Immunity</i> , 2002, 2, 5.	3.2	31
85	A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. <i>Oncology</i> , 2012, 82, 333-340.	0.9	29
86	Cancer immunotherapy in clinical oncology. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, S46-S51.	1.1	27
87	Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 325-338.	2.0	27
88	Radiotherapy supports protective tumor-specific immunity. <i>Oncolimmunology</i> , 2012, 1, 1610-1611.	2.1	27
89	Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. <i>BMC Cancer</i> , 2018, 18, 72.	1.1	26
90	An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer. <i>Oncology Research and Treatment</i> , 2007, 30, 355-360.	0.8	25

#	ARTICLE	IF	CITATIONS
91	Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. <i>International Journal of Cancer</i> , 2007, 121, 2042-2048.	2.3	25
92	Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. <i>European Journal of Dermatology</i> , 2008, 18, 566-70.	0.3	25
93	Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line. <i>Hepatology</i> , 1994, 19, 145-154.	3.6	24
94	Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. <i>Journal of Immunology</i> , 2006, 177, 8212-8218.	0.4	24
95	Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 871-881.	2.0	23
96	Cellular and humoral immune responses against cancer: implications for cancer vaccines. <i>Current Opinion in Immunology</i> , 1991, 3, 659-664.	2.4	22
97	Cancer testis antigen expression in testicular germ cell tumorigenesis. <i>Modern Pathology</i> , 2014, 27, 899-905.	2.9	22
98	Hepatocellular carcinoma after thorotrast exposure: Establishment of a new cell line (Mz-Hep-1). <i>Hepatology</i> , 1985, 5, 1112-1119.	3.6	21
99	Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – A phase II study. <i>Gynecologic Oncology</i> , 2009, 112, 384-388.	0.6	21
100	Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. <i>Annals of Hematology</i> , 2010, 89, 783-787.	0.8	21
101	Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15187-15192.	3.3	21
102	Antibodies and vaccines – hope or illusion?. <i>Breast</i> , 2005, 14, 631-635.	0.9	20
103	Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. <i>International Journal of Cancer</i> , 2005, 117, 800-806.	2.3	20
104	Distinct expression patterns of the immunogenic differentiation antigen NY-ESO-1 in normal breast, testis and their malignant counterparts. <i>International Journal of Cancer</i> , 2008, 122, 1585-1591.	2.3	20
105	Liver Perfusion Imaging in Patients with Primary and Metastatic Liver Malignancy. <i>Academic Radiology</i> , 2012, 19, 613-621.	1.3	20
106	Targeted therapeutic approach for an anaplastic thyroid cancer <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Science</i> , 2008, 99, 1847-1852.	1.7	18
107	Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. <i>Lung Cancer</i> , 2012, 76, 118-122.	0.9	18
108	Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. <i>Cancer Immunology Research</i> , 2016, 4, 18-25.	1.6	18

#	ARTICLE	IF	CITATIONS
109	Potential use of humanized antibodies in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1065-1074.	1.1	17
110	Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 249-258.	2.0	17
111	Increased Bone Marrow Activity on F-18-FDG PET/CT in Granulocyte Colony Stimulating Factor Producing Anaplastic Thyroid Carcinoma. <i>Clinical Nuclear Medicine</i> , 2010, 35, 103-104.	0.7	17
112	Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus. <i>Vaccines</i> , 2020, 8, 116.	2.1	17
113	Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue. <i>International Journal of Cancer</i> , 2002, 97, 64-71.	2.3	16
114	Frequent expression of the breast differentiation antigen NY-BR-1 in mammary and extramammary Paget's disease. <i>Pathology International</i> , 2010, 60, 726-734.	0.6	16
115	The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. <i>Vaccine</i> , 2011, 29, 3832-3836.	1.7	16
116	Abstract B1: Radiotherapy promotes tumor-specific effector CD8+ T cells via DC activation.. , 2013, , .		16
117	Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. <i>Annals of Hematology</i> , 2011, 90, 89-94.	0.8	15
118	Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer. <i>Case Reports in Oncology</i> , 2011, 4, 16-18.	0.3	15
119	Innovation Can Improve And Expand Aspects Of End-Of-Life Care In Low- And Middle-Income Countries. <i>Health Affairs</i> , 2014, 33, 1612-1619.	2.5	15
120	NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. <i>Cancer Immunity</i> , 2013, 13, 12.	3.2	15
121	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. <i>Cancer Immunity</i> , 2002, 2, 12.	3.2	14
122	Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A. , 1999, 81, 979-984.		13
123	Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 565-574.	1.4	13
124	Target level blocking of T-cell cytotoxicity for human malignant melanoma by monoclonal antibodies. <i>Cellular Immunology</i> , 1984, 83, 398-403.	1.4	12
125	Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent Patient. <i>Case Reports in Oncology</i> , 2013, 6, 497-503.	0.3	12
126	Imagine a world without cancer. <i>BMC Cancer</i> , 2014, 14, 186.	1.1	12



#	ARTICLE	IF	CITATIONS
127	Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. <i>International Journal of Cancer</i> , 2006, 118, 668-674.	2.3	11
128	The effect of protein mutations on drug binding suggests ensuing personalised drug selection. <i>Scientific Reports</i> , 2021, 11, 13452.	1.6	11
129	Cryptic Epitopes Induce High-Titer Humoral Immune Response in Patients with Cancer. <i>Journal of Immunology</i> , 2010, 185, 3095-3102.	0.4	10
130	Developments in Cancer Immunotherapy. <i>Digestive Diseases</i> , 2010, 28, 51-56.	0.8	10
131	Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates. <i>Cancer Immunology Research</i> , 2014, 2, 404-409.	1.6	10
132	Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. <i>Oncology</i> , 2021, 99, 300-309.	0.9	10
133	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. <i>Cancer Immunity</i> , 2013, 13, 3.	3.2	10
134	Messenger RNA vaccination and B-cell responses in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2573-2573.	0.8	9
135	Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3. <i>International Journal of Cancer</i> , 1993, 55, 465-470.	2.3	8
136	Impact of Antigen Presentation on TCR Modulation and Cytokine Release: Implications for Detection and Sorting of Antigen-Specific CD8+ T Cells Using HLA-A2 Wild-Type or HLA-A2 Mutant Tetrameric Complexes. <i>Journal of Immunology</i> , 2002, 168, 2766-2772.	0.4	8
137	Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. <i>Swiss Medical Weekly</i> , 2011, 141, w13203.	0.8	8
138	The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines. <i>Cancer Immunity</i> , 2012, 12, 6.	3.2	8
139	Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. <i>Oncology</i> , 2010, 79, 93-97.	0.9	7
140	Spontaneous Peripheral T-cell Responses toward the Tumor-Associated Antigen Cyclin D1 in Patients with Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2013, 1, 288-295.	1.6	7
141	RP1 Is a Phosphorylation Target of CK2 and Is Involved in Cell Adhesion. <i>PLoS ONE</i> , 2013, 8, e67595.	1.1	7
142	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. , 1996, 66, 162.		6
143	NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. <i>Yeast</i> , 2010, 27, 919-931.	0.8	5
144	Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. <i>Cancer Immunity</i> , 2009, 9, 2.	3.2	5

#	ARTICLE	IF	CITATIONS
145	Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. <i>Anticancer Research</i> , 2014, 34, 4693-9.	0.5	5
146	Performance of different data sources in identifying adverse drug events in hospitalized patients. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 909-918.	0.8	4
147	Status of hepatocellular carcinoma in Gulf region. <i>Chinese Clinical Oncology</i> , 2013, 2, 42.	0.4	4
148	Antigen recognition by T cells: a strong sense of structure. <i>Trends in Immunology</i> , 2001, 22, 599-601.	2.9	3
149	Infarction-Like Electrocardiographic Changes Due to a Myocardial Metastasis From a Primary Lung Cancer. <i>Circulation</i> , 2007, 115, e320-1.	1.6	3
150	Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 1279-1288.	1.6	3
151	Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. <i>Swiss Medical Weekly</i> , 2013, 143, w13791.	0.8	3
152	Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 1994, 39, 93-99.	2.0	3
153	Response to monoclonal antibodies in melanoma: Specific or non-specific?. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1986, 22, 1285-1288.	0.9	2
154	Targeted Exome Sequencing Identifies Novel Mutations in Familial Myeloproliferative Neoplasms Patients in the State of Qatar. <i>Blood</i> , 2014, 124, 5570-5570.	0.6	2
155	Cancer immunity hits multiple myeloma. <i>Blood</i> , 2005, 105, 3765-3766.	0.6	1
156	Challenges In Adapting International Best Practices In Cancer Prevention, Care, And Research For Qatar. <i>Health Affairs</i> , 2014, 33, 1635-1640.	2.5	1
157	Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?. <i>Visceral Medicine</i> , 2015, 31, 434-439.	0.5	1
158	Chromosomal aberrations of cancerâ€™testis antigens in myeloma patients. <i>Hematological Oncology</i> , 2015, 33, 159-163.	0.8	1
159	Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 685-695.	0.6	1
160	Differentiation of Non-Adherent Hematopoietic Stem Cells from Umbilical Cord Blood Cells into Adherent Hepatocytic Lineage.. <i>Blood</i> , 2006, 108, 2578-2578.	0.6	1
161	Undifferentiated sarcoma arising in the brain, 23Âyears after curative treatment of an ependymoma. <i>Journal of Neuro-Oncology</i> , 2005, 72, 239-239.	1.4	0
162	Antibody and T-cell responses to the NY-ESO-1 antigen. , 2003, , 191-197.		0

#	ARTICLE	IF	CITATIONS
163	Expansion of Umbilical Cord Blood Hematopoietic Stem Cells for Clinical Use.. Blood, 2007, 110, 4049-4049.	0.6	0
164	Abstract 5530: Evidence for immunological pressure and escape from longitudinal analysis of the expression of and immune responses against NY-ESO-1 in a patient with metastatic melanoma. , 2011, , .		0
165	Abstract 5516: Therapeutic vaccination with the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. , 2011, , .		0
166	Abstract 4741: Therapeutic efficacy of a human-derived antibody against cancer-testis antigen NY-ESO-1. , 2011, , .		0
167	Abstract A18: Mouse models of autochthonous cancer to study local immune subversion.. , 2013, , .		0